Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel–Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3-Reference-Cited by-同舟云学术

Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel–Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3

Published:2020-08-13 Issue:1 Volume:20 Page:41-53
ISSN:1473-4222
Container-title:The Cerebellum
language:en
Short-container-title:Cerebellum

Author:

Bushart David D.,Zalon Annie J.,Zhang Hongjiu,Morrison Logan M.,Guan Yuanfang,Paulson Henry L.,Shakkottai Vikram G.,McLoughlin Hayley S.^ORCID

Funder

National Institute of Neurological Disorders and Stroke

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s12311-020-01179-7.pdf

Reference50 articles.

1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9(9):885–94.

2. Gardiner SL, Boogaard MW, Trompet S, de Mutsert R, Rosendaal FR, Gussekloo J, et al. Prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among large population-based cohorts. JAMA Neurol. 2019;76(6):650–6.

3. McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis. 2020;134:104635.

4. Seidel K, Siswanto S, Brunt ERP, den Dunnen W, Korf HW, Rub U. Brain pathology of spinocerebellar ataxias. Acta Neuropathol. 2012;124(1):1–21.

5. Rub U, Schols L, Paulson H, Auburger G, Kermer P, Jen JC, et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol. 2013;104:38–66.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insight into the early pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3/machado–joseph disease from mouse models;Parkinsonism & Related Disorders;2024-09

2. Emerging therapies in hereditary ataxias;Trends in Molecular Medicine;2024-08

3. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice;Molecular Therapy;2024-05

4. Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?;Cells;2024-02-09

5. Proteome landscape and interactome of voltage-gated potassium channel 1.6 (Kv1.6) of the murine ophthalmic artery and neuroretina;International Journal of Biological Macromolecules;2024-02